About Danio Labs
Developer of therapeutics for neurological, ophthalmological, and metabolic diseases. The company's two main objectives are investigating new uses for established drugs (reprofiling), and providing phenotypic evaluation of compounds for other organisations, either for activity effects, or for preclinical safety pharmacology. As part of the company's approach, zebrafish are used as a key enabling technology. Their size allows them to be used to evaluate the effects of compounds in human disease models.